Tuberculosis, caused by Mycobacterium tuberculosis infection, remains a global threat to human health, but knowledge of the molecular mechanisms underlying the pathogenesis of tuberculosis is still limited. Although Notch4, a member of the Notch receptor family, is involved in the initiation of mammary tumors, its function in M. tuberculosis infection remains unclear. In this study, we found that Notch4-deficient mice were more resistant to M. tuberculosis infection, with a much lower bacterial burden and fewer pathological changes in the lungs. Notch4 inhibited M. tuberculosis-induced production of proinflammatory cytokines by interaction with TAK1 and inhibition of its activation. Furthermore, we found that Notch intracellular domain 4 prevented TRAF6 autoubiquitination and suppressed TRAF6-mediated TAK1 polyubiquitination. Finally, Notch inhibitors made mice more resistant to M. tuberculosis infection. These results suggest that Notch4 is a negative regulator of M. tuberculosis-induced inflammatory response, and treatment with a Notch inhibitor could serve as a new therapeutic strategy for tuberculosis.
Mycobacterium tuberculosis remains the leading bacterial cause of death in humans throughout the world [1] . In 2015, M. tuberculosis was responsible for 10.4 million new infections and 1.8 million deaths [2] . Therefore, identification of key host factors involved in the pathogenesis of tuberculosis and the discovery of new signaling pathways modulating M. tuberculosis infection will aid the development of novel therapeutic approaches and the improvement of current vaccination strategies.
The recognition of M. tuberculosis or mycobacterial products by Toll-like receptors (TLRs) is important for the initiation of the innate immune responses [3] , which is the first line of the host defense against M. tuberculosis. TLRs recruit adaptor proteins, such as MyD88, IRAK, and TRAF6 [4] [5] [6] . The recruitment of these adaptors activates TAK1 and its downstream effectors, including NF-κB and MAPK (eg, ERKs, JNKs, and p38). Activation of these signaling pathways leads to the biosynthesis of proinflammatory cytokines, such as tumor necrosis factor α, interleukin 6 (IL-6), interleukin 12 (IL-12), proinflammatory interleukin 1β and proinflammatory interleukin 18, which serve as important innate immune mediators and are critical for the initiation and shaping of adaptive immunity [7] .
Notch4 is a member of Notch receptor family and an evolutionarily conserved transmembrane receptor. Following the binding of ligands on adjoining cells, such as Delta and Serrate/ Jagged families, the Notch receptor undergoes cleavage at the membrane, which leads to the release of the Notch-intracellular domain (NICD), followed by translocation to the nucleus and regulation of gene transcription [8] . Accumulating evidence indicates that the Notch signaling pathway plays critical roles in regulating innate and adaptive immunity and that aberrant Notch signaling is associated with inflammatory disease [9, 10] . A recent study indicated that Notch4 was critical to the innate immune inflammatory response of the lung to ozone [11] . However, the role of Notch4 in M. tuberculosis infection remains unclear.
Here, we showed that Notch4 deficiency resulted in resistance to M. tuberculosis infection in mice, which correlated with an enhanced inflammatory response. Furthermore, Notch4 inhibited the M. tuberculosis-triggered production of proinflammatory cytokines in macrophages through the inhibition of phosphorylation and ubiquitination of TAK1. Last, the Notch inhibitor DAPT was shown to ameliorate M. tuberculosis infection. Therefore, we have demonstrated for the first time that Notch4 is important to the regulation of the M. tuberculosis infection by negatively regulating the inflammatory responses, which makes it an attractive target for host-targeted therapy against tuberculosis.
METHODS

Patients
The diagnosis of tuberculosis was based on clinical presentation and radiological signs and was confirmed by sputum culture positivity. Tuberculosis cases were excluded if human immunodeficiency virus positive. The average age was 48 years, and 71% of patients were male. All protocols were approved by the local ethics committee (permit number 2011-FK-03), and signed informed consent was obtained from subjects.
Cell, Antibodies, and Reagents
HEK293T and RAW 264.7 cells were purchased from ATCC. Mouse peritoneal macrophages were isolated as previously described [12] . Briefly, mice were injected intraperitoneally with 2.0 mL of 4% Brewer's thioglycollate medium (SigmaAldrich). After 3 days, primary macrophages were collected by peritoneal lavage from euthanized animals, using 10 mL of cold phosphate-buffered saline (PBS). Peripheral blood mononuclear cells (PMBCs) were isolated from ethylenediaminetetraacetic acid-treated whole blood, using Ficoll density gradient centrifugation. 5Z-7-oxozeaenol (5Z-7-OX) was purchased from Sigma-Aldrich (O9890; Sigma); The γ-secretase inhibitor compound E [13] and DAPT were from Enzo Life Sciences (ALX-270-415) and Selleckchem (S2215),respectively. SB203580 and PDTC (Calbiochem) were used at 10 μM. Rabbit anti-Notch4 (sc-5594), rabbit anti-TAK1 (sc-7162), and rabbit anti-TRAF6 (sc-7221) were from Santa Cruz Biotechnology. Rabbit anti-phosphorylated TAK1 (Ser187; 4536), rabbit anti-K63-linkage specific polyubiquitin (5621), rabbit anti-phosphorylated p65 (3033), rabbit anti-phosphorylated p38 (9215), and rabbit anti-phosphorylated JNK (9251) were from Cell Signaling Technology. Monoclonal mouse anti-Flag M2 affinity gel (A2220), monoclonal mouse anti-HA (H9658), rabbit anti-HA (H6908), rabbit anti-GAPDH (SAB2701826), rabbit anti-Myc (M4439), and rabbit anti-Flag (F7425) were from Sigma.
Plasmids Construction
The wild-type PBSK Notch4 plasmid was obtained from Addgene (plasmid 21325). Notch4 intracellular domain (NICD4; 4382-6043) was prepared by polymerase chain reaction (PCR) analysis and cloned into pcDNA-3.1 with a Flag, HA, or Myc tag. The NICD4 deletion mutants were constructed as previously described [14] . Notch1 intracellular domain (NICD1) and Notch2 intracellular domain (NICD2) were kindly provided by Dr Raphael Kopan (Washington University, St. Louis, MO) [15] . Flag-tagged MyD88, TAK1, TAK1-N, TAK1-C, TRAF6, p38, p85, HA-tagged TAK1, ubiquitination, and K63-linked ubiquitination plasmids were described previously [16] [17] [18] . TAK1 was cloned into pGEX-4T-1 for the production of a glutathione S-transferase (GST) fusion protein. NICD4 was cloned into pET28a for the production of a His fusion protein.
Mice and Aerosol-Based Infection
Notch4 −/− mice (B6; 129 S1-Notch4 tm1Grid/J ; stock 010544) were obtained from the Jackson Laboratory and C57BL/6 mice from Shanghai Laboratory Animal Center. All mice were bred under specific-pathogen-free conditions at the Laboratory Animal Center of Tongji University. Female mice (age, 6-8 weeks) were used in the study. Infection studies were performed using a murine respiratory infection model as previously described [19] . Mice were infected with approximately 200 colony-forming units (CFU) of M. tuberculosis H37Rv, using a Glas-Col inhalation exposure system (Glas-col, Terre Haute, IN). Four weeks after infection, mice were euthanized, and bacterial counts in the lungs were determined.
For 5Z-7-OZ treatment, the specific TAK1 inhibitor 5Z-7-OZ was administered intraperitoneally to female Notch4 -/-and wild-type (WT) mice at a dose of 2 mg/kg [20, 21] . Three days after the initial 5Z-7-OZ or vehicle control treatment, the mice were infected with M. tuberculosis as previously described and then exposed to 5Z-7-OZ once weekly for 4 weeks.
DAPT Treatment
DAPT was dissolved in dimethyl sulfoxide (DMSO; SigmaAldrich) at 80 mg/mL as a stock solution or dissolved in corn oil at 1.2 mg/mL for mouse treatment. Specifically, the DAPT solution or vehicle solution was prepared freshly by combining the DAPT stock solution or DMSO with corn oil at a ratio of 92.5% corn oil to 7.5% DMSO. WT mice were infected with M. tuberculosis as previously described. Two weeks later, the mice were randomized into study groups and then received 6 mg/kg DAPT or vehicle by intraperitoneal injection on alternate days for 4 weeks.
Histological Analysis and Acid-Fast Staining
Lungs from M. tuberculosis-infected mice were fixed in 4% phosphate-buffered formalin for 24 hours and embedded in paraffin wax. Hematoxylin-eosin staining was performed to detect the infiltration in the lungs. Acid-fast staining using the standard Ziehl-Neelsen method was used for the visualization of M. tuberculosis.
Flow Cytometry
Single-cell suspensions were obtained from spleens of M. tuberculosis-infected mice. Erythrocytes were removed, and then cells were stimulated with PMA (10 ng/mL, Sigma-Aldrich) plus ionomycin (1 mg/mL, Sigma-Aldrich) and brefeldin A (SigmaAldrich) for 6 hours. Cells were fixed with 4% formaldehyde and stained with anti-CD4 and anti-CD3 in PBS containing 1% fetal bovine serum, followed by permeabilization with 0.5% saponin for intracellular staining with anti-interleukin 17 (IL-17; eBioscience) and anti-interferon γ (IFN-γ; eBioscience). Cells producing IFN-γ and IL-17 were detected by flow cytometry (BD Accuri C6).
Western Blot and Immunoprecipitation Analysis
For immunoprecipitation analysis, HEK293T cells were used for transient expression, and whole-cell extracts were incubated overnight with the appropriate antibodies, together with Protein A/G or Flag beads. The beads were then washed 3 times, and immunoprecipitates were resolved by polyacrylamide gel electrophoresis. The proteins were transferred to a polyvinylidene difluoride membrane and then incubated with the appropriate antibodies.
RNA Interference and Transfection
RAW 264.7 cells were transfected with a Notch4 small interfering RNA (siRNA) mixture, using Interfer (Polyplus Transfection), for 48 hours. The sequences of siRNA (GenePharma, China) are listed in Supplementary Table 1 .
Quantitative PCR (qPCR), ELISA, and GST Precipitation
Total RNA was reverse transcribed using the ReverTra Ace realtime qPCR kit (Toyobo, FSQ-101). A SYBR real-time PCR kit (Toyobo, QPK-212) was used for real-time qPCR analysis. The sequences of the qPCR primers are presented in Supplementary  Table 1 . ELISA and GST precipitation were performed as previously described [17] .
Cell Viability Assay
The effect of the Notch inhibitor (compound E) on cell proliferation was determined using the Cell Counting Kit-8 (CCK8, Beyotime, China) according to the manufacturer's protocol.
Statistical Analysis
All data are expressed as mean values ± standard errors of the mean unless otherwise indicated. A 2-tailed Student t test was used to compare the means between 2 groups, and 2-way analysis of variance followed by Bonferroni post hoc test was used for multiple comparisons. Bacterial titers were analyzed using the Mann-Whitney U test. All analyses were performed using Graph-Pad Prism 5.0 software. A P value of <.05 was considered statistically significant.
RESULTS
Notch4-Deficient Mice Are More Resistant to M. tuberculosis Infection
To assess the role of Notch4 in the pathogenesis of tuberculosis in vivo, WT and Notch4 -/-mice were infected with M. tuberculosis for 4 weeks. M. tuberculosis-infected Notch4 -/-mice exhibited a decreased bacterial burden in their lungs, as indicated by both the CFU assay and acid-fast staining ( Figure 1A ). Fewer pathological changes were observed in the lungs of M. tuberculosis-infected Notch4 -/-mice, compared with WT mice ( Figure 1B ). Furthermore, we analyzed the expression of cytokines in the lungs of infected mice and found a higher level of proinflammatory cytokines, including Il-6, Il-12b, and Ifn-γ messenger RNA in Notch4 -/-mice ( Figure 1C ). By quantification of splenic T-helper type 1 (Th1) and Th17 cells using flow cytometry, more IFN-γ + CD4 + T cells were observed in the spleens of Notch4 -/-mice, compared with WT mice ( Figure 1D ). The number of IL-17A + CD4 + T cells was not changed ( Figure 1D ). The fact that Notch4 -/-mice were more resistant to M. tuberculosis infection suggested that Notch4 might negatively regulate the host immune response to M. tuberculosis infection in vivo.
Notch4 Inhibits M. tuberculosis-Induced Inflammatory Cytokines in
Macrophages
M. tuberculosis infection first triggers the activation of innate immunity. To define the function of Notch4 in the innate immune response to M. tuberculosis infection, we analyzed the effect of Notch4 on the production of proinflammatory cytokines in macrophages. Peritoneal macrophages were pretreated with the Notch inhibitor compound E, which blocked γ-secretase and prevented the generation of the NICD, and then infected with M. tuberculosis. Treatment with compound E markedly increased the expression of the proinflammatory cytokines Il-6 and Il-12b in macrophages infected with M. tuberculosis ( Figure 2A ). We also found that, at a concentration of 10 μM, compound E did not significantly affect cell viability (Supplementary Figure 1A) or M. tuberculosis phagocytosis (Supplementary Figure 1B) . Moreover, in response to M. tuberculosis infection, Notch4 -/-macrophages or RAW 264.7 cells transfected with Notch4 siRNA produced much more Il-6 and Il-12b than WT macrophages or RAW 264.7 cells transfected with control siRNA ( Figure 2B and Supplementary Figure 3D ). In parallel, we analyzed the production of Notch4 protein in peripheral blood mononuclear cells (PBMCs) and the production of IL-6 in sera from 25 patients with tuberculosis. A reverse correlation between the expression of Notch4 and the production of IL-6 was observed (Spearman r = -0.646; P = .0005; Figure 2C ). Together, these results suggest that Notch4 might act as a negative regulator of inflammatory response to M. tuberculosis infection.
Notch4 Interacts with TAK1 and Inhibits Its Activation
TLR pathways play an important role in the regulation of inflammatory response to microbial infection. We examined the association between NICD4 and various components of the TLR pathways by coimmunoprecipitation analysis (Supplementary Figure 2A) . NICD4 interacted with TAK1, which was dependent on the C-terminal domain of TAK1 ( Figure 3A) . TAK1 also interacted with the intracellular domain of other Notch receptors, including Notch1 and Notch2 (Supplementary Figure 2B) . In addition, the recruitment of endogenous Notch4 to TAK1 was enhanced in primary peritoneal macrophage cells and RAW 264.7 cells infected with M. tuberculosis, suggesting a stimulus-regulated interaction between NICD4 and TAK1 ( Figure 3B and Supplementary Figure 3C) . Recombinant histidine-tagged (His)-Notch4 also bound to purified GST-fused TAK1, indicating a direct interaction between Notch4 and TAK1 ( Figure 3C) . Coimmunoprecipitation experiments using Data are presented as the medians ± interquartile ranges and were analyzed by the Mann-Whitney U test (*P < .05 is significant). Acid-fast staining of M. tuberculosis in the lungs of mice (bar, 20 µm; original magnification ×1000). B, Hematoxylin-eosin staining of lungs from Notch4 +/+ or Notch4 -/-mice (bar, 100 µm; original magnification ×200). C, Quantitative polymerase reaction analysis of Il-6, Il-12b, or Ifn-γ messenger RNA (mRNA) in the lungs of Notch4 +/+ or Notch4 -/-mice. D, Intracellular staining for interferon γ (INF-γ) or interleukin 17A (IL-17A) among CD4 + T lymphocytes in splenocytes was measured by flow cytometry. Plots shown were gated on CD3 + CD4 + T cells. Results shown in panels C and D are expressed as mean values ± standard errors of the mean and analyzed by the Student t test (*P < .05, **P < .01, and ***P < .001). All data are representative of 3 independent experiments. NS, not significant; PBS, phosphate-buffered saline.
NICD4 deletion mutants revealed that >1 domain of NICD4 interacts with TAK1 (Supplementary Figure 2C) . To further define whether the Notch4 regulates TAK1 activation, HEK293T cells were transfected with NICD4, and TAK1 phosphorylation was analyzed by Western blotting using an anti-phosphorylated TAK1 antibody. Overexpression of NICD4 in HEK293T cells markedly inhibited the phosphorylation of TAK1 at Thr187. In response to M. tuberculosis infection, enhanced phosphorylation of TAK1 was observed for Notch4 -/-peritoneal macrophages, compared with the WT controls ( Figure 3D ). To evaluate the correlation of the abundance of Notch4 with TAK1 activation in patients with tuberculosis, the phosphorylation of TAK1 and expression of Notch4 were detected by Western blotting in PBMCs from 24 patients with tuberculosis and compared to the control gene GAPDH, based on the intensities of each band. Expression of Notch4 was negatively correlated with TAK1 activation (Spearman r = -0.4906; P = .0149; Supplementary Figures 2D) , Therefore, Notch4 might play a negative role in the activation of TAK1 in the pathogenesis of tuberculosis. 
NICD4 Inhibits TAK1 Downstream MAPK and NF-κB Pathway Activation
We examined the effect of Notch4 on the activation of NF-κB and MAPK pathways. Upon infection with M. tuberculosis, Notch4 -/-macrophages exhibited markedly enhanced phosphorylation of p38 and NF-κB, compared with WT macrophages ( Figure 4A ). Pretreatment of WT or Notch4 -/-primary peritoneal macrophages with specific p38 or NF-κB inhibitors significantly reduced M. tuberculosis-induced production of IL-6. It also eliminated the enhancement effects of Notch4 deficiency ( Figure 4B and 4C). These data suggest that Notch4 may inhibit M. tuberculosis-induced production of proinflammatory cytokines by suppressing the activation of the NF-κB and MAPK pathways.
Notch4 Inhibits M. tuberculosis-Induced Inflammatory Cytokines via TAK1
To further define whether Notch4 inhibits cytokines via TAK1, we pretreated macrophages with 5Z-7-OZ, a selective inhibitor of TAK1 [22] , before M. tuberculosis infection. 5Z-7-OZ markedly decreased M. tuberculosis-induced expression of Il-6 and Il-12b and also eliminated the enhancement effects of Notch4 deficiency on M. tuberculosis-induced expression of Il-6 and Il-12b ( Figure 5A ). To further confirm the relevance of TAK1 activation for the effects of Notch4 in vivo, we treated the WT or Notch4 -/-mice with 5Z-7-OZ 3 days before M. tuberculosis . B, Notch4 +/+ or Notch4 -/-mice were treated with 5Z-7-OZ at 2 mg/kg before undergoing M. tuberculosis infection for 3 days and then were treated once weekly for 4 weeks. The bacterial burden in the lungs of mice treated with 5Z-7-OZ was measured using the colony-forming units assay. Data are presented as median values ± the interquartile ranges and were analyzed by the Mann-Whitney U test; C, Hematoxylin-eosin staining of lungs from 5Z-7-OZ treated or untreated mice (bar, 100 µm; original magnification ×200). D, qPCR of Il-6 or Il-12b mRNA in lungs of mice treated with 5Z-7-OZ. The results are expressed as mean values ± standard errors of the mean of 3 independent experiments. The Student t test and 2-way analysis of variance followed by the Bonferroni post hoc test were used for statistical analyses. # P < .05, ## P < .01, and ### P < .001 for comparison of each experimental condition to medium control in the Notch4 +/+ and Notch4 -/-groups; & P < .05, && P < .01, and &&& P < .001 for comparison of M. tuberculosis plus inhibitor to M. tuberculosis in the Notch4 +/+ and Notch4 -/-groups; and *P < .05, ** P < .01, and *** P < .001 for comparison between the Notch4 +/+ and Notch4 -/-groups per experimental condition. For panels B-D, there were 10 mice/group. DMSO, dimethyl sulfoxide; NS, not significant.
Notch4 -/-mice infected with M. tuberculosis ( Figure 5B and 5C) . Furthermore, inhibition of TAK1 alleviated the enhanced production of Il-6 and Il-12b in the lungs of Notch4 -/-mice infected with M. tuberculosis ( Figure 5D ). Together, these data suggest that the negative regulation of M. tuberculosis-induced cytokine expression by Notch4 is largely dependent on suppressing the activation of TAK1.
NICD4 Interacts With TRAF6 and Prevents Its Autoubiquitination
The activation of TAK1 is a ubiquitination-dependent process [23] . In HEK293T cells, overexpression of NICD4 noticeably reduced the K63-linked ubiquitination of TAK1 ( Figure 6A ). Upon infection with M. tuberculosis, endogenous K63-linked ubiquitination of TAK1 was increased in Notch4 -/-macrophages and RAW 264.7 cells transfected with Notch4 siRNA, compared with WT macrophages or RAW 264.7 cells transfected with control siRNA ( Figure 6A and Supplementary Figure 3C) . These results suggest that Notch4 suppresses K63-linked ubiquitination of TAK1. TRAF6 is an E3 ligase that regulates ubiquitination-dependent activation of the TAK1 complex [24, 25] . In HEK293T cells expressing Flag-TRAF6 and HA-tagged NICD4, we found that NICD4 interacted with TRAF6 ( Figure 6B) . Similarly, TRAF6 also interacted with NICD1 and NICD2 (Supplementary Figure 3A) . In addition, >1 domain of NICD4 interacted with TRAF6 (Supplementary Figure 3B) .
TRAF6 activation depends on its K63-linked ubiquitination. In HEK293T cells, overexpression of NICD4 markedly inhibited the total or K63-linked ubiquitination of TRAF6 ( Figure 6C ). To investigate whether NICD4 is involved in TRAF6-mediated ubiquitination of TAK1, TAK1, HA-tagged K63-linked ubiquitin, and Flag-tagged TRAF6 were transfected into HEK293T cells in the presence or absence of Myc-tagged NICD4. Subsequently, immunoprecipitation experiments were performed. Coexpression of NICD4 significantly reduced the TRAF6-mediated K63-linked ubiquitination of TAK1 ( Figure 6D ). Together, these results suggest that Notch4 may prevent TAK1 ubiquitination through TRAF6.
Notch Inhibitor Ameliorates M. tuberculosis Infection
To investigate whether the beneficial effects of the suppression of Notch signaling could be translated into host-directed therapy, we investigated the in vivo effect of DAPT, a γ-secretase inhibitor that strongly inhibits Notch activity, on M. tuberculosis infection. First, WT mice were infected with M. tuberculosis via the aerosol route. Two weeks later, the mice were treated with 6 mg/kg DAPT [26] on alternate days. Six weeks after infection, Il-6, Il-12b, and Ifn-γ were markedly increased in the lungs of the DAPT-treated group ( Figure 7A ). In addition, mice treated with DAPT harbored a relatively lower bacterial load and fewer pathological changes in their lungs ( Figure 7B-D) . Together, these results demonstrate a therapeutic effect of Notch inhibitor against M. tuberculosis infection in mice.
DISCUSSION
Notch4 is well documented to play an important role in the carcinogenesis of several tumors [27] [28] [29] . However, the function of Notch4 signaling in the process of bacterial infection, such as that due to M. tuberculosis, is still largely unknown. In a previously study, we found that Notch4 is a gene conferring susceptibility to tuberculosis (data not published). Here, we found that Notch4-deficient mice or mice treated with a Notch inhibitor were more resistant to M. tuberculosis infection. Notch4 interacted with TRAF6/TAK1 and suppressed the activation of TAK1, which inhibited the production of the proinflammatory cytokines IL-6 and IL-12b. These data suggested that Notch4 is a negative regulator of the host inflammatory response against M. tuberculosis infection and that treatment with a Notch inhibitor may serve as a new therapeutic strategy against tuberculosis. Innate immunity is an evolutionarily conserved defense mechanism against microbial pathogens and is essential for the activation of the adaptive immune response. Proinflammatory cytokines, such as IL-6 and IL-12, appear to be the determining regulators of M. tuberculosis infection [30] . IL-12-deficient mice are highly susceptible to mycobacterial infections, with a reduced capacity to produce IFN-γ [31, 32] . IL-6-deficient mice fail to control bacterial growth and exhibit increased mortality, indicating a protective role of IL-6 during M. tuberculosis infection [33] . Blocking IL-6 or IL-12 increases the susceptibility of mice to M. tuberculosis infection [34, 35] . In this study, we found that Notch4 deficiency enhanced the M. tuberculosistriggered expression of Il6 and Il12 in macrophages or in a murine infection model. One critical role for IL-12 is to promote the development of IFN-γ-producing CD4 + Th1 cells [36, 37] , which participate in protective immunity against tuberculosis [38] . In our study, Notch4 deficiency led to a higher number of IFN-γ-secreting Th1 cells and reduced bacterial burden and lungs damage in M. tuberculosis-infected mice. It is tempting to speculate that the deficiency of Notch4 protected mice against M. tuberculosis infection by modulating T-cell immune response, especially Th1 differentiation or expansion. This hypothesis warrants further study. Clinically, patients with tuberculosis have a higher abundance of Notch4 but a lower amount of IL-6. This inverse correlation suggests that differences in Notch4 expression might lead to divergent inflammatory states and different disease outcomes. Taken together, these results suggest that Notch4 is an important negative regulator in the pathogenesis of tuberculosis, at least partially through the suppression of the inflammatory responses to M. tuberculosis infection.
Notch signaling depends on its active form, NICD, that translocates into the nucleus, where it interacts with the transcription factor RBP-J to form a transcriptional activator complex and induce transcription of Notch downstream target genes, such as basic helix-loop-helix family (Hes1 and Hes5) and the HESR family of transcription factors (ie, Hey1 and Hey2) [39] . The Notch signal mediates a feedback inhibition of TLR-induced cytokines through its target genes, Hes1 and Hey1 [40, 41] . However, we found that Notch4 interacts with TAK1 and TRAF6 and that the interaction of Notch4 with TAK1 inhibits the K63-linked ubiquitination and phosphorylation of TAK1. TAK1 plays an important role in TLR-induced production of proinflammatory cytokines by regulating activation of MAPK and NF-κB pathways [23] . TRAF6 forms a complex with TAK1 and activates TAK1 in a ubiquitination-dependent manner [42] . In this study, we found that Notch signaling inhibited the inflammatory response to M. tuberculosis largely via suppression of ubiquitin-mediated activation of TAK1. Thus, these findings provide an alternative mechanism for Notch signaling that negatively regulates innate inflammatory responses outside of its transcriptional activity. In addition, our findings show a new mechanistic explanation for the cross-talk between Notch and TLR signaling pathways in macrophages.
The Notch inhibitor is a γ-secretase inhibitor, which mediates the proteolytic cleavage of the Notch receptor to generate the NICD. Previous studies showed that compound E and DAPT inhibited NICD generation and downstream transcriptional activation by suppressing the activity of γ-secretase [13] . Notch signaling has long been considered a potential therapeutic target for cancer [43, 44] , and Notch inhibitors have already been tested in phase 1 and phase 2 trials [45] [46] [47] . Interestingly, treatment with DAPT protected mice from M. tuberculosis infection, as demonstrated by reduced pathological changes in the lungs, lower bacterial load, and higher expression of Th1-type cytokines. In our study, we found that both genetic ablation of Notch4 and treatment with the γ-secretase inhibitor increased the resistance to tuberculosis both in vitro and in vivo. Although we could not exclude the possibility that these compounds promoted the inflammation in a Notch4-independent manner, our results clearly showed that Notch4 played an important role in M. tuberculosis-induced cytokine production and the pathogenesis of tuberculosis. The beneficial effect of Notch inhibition against M. tuberculosis infection indicates that Notch signaling might be a potential therapeutic target for host-targeted therapy against tuberculosis. The data presented here further our understanding of the immune regulation of M. tuberculosis infection. These studies not only provide novel mechanistic insights into tuberculosis pathogenesis but also identify potential molecular targets for developing host-directed treatments against tuberculosis.
